Interfacing chemical biology and drug discovery: report from the 50th International Conference on Medicinal Chemistry of the SCT (French Medicinal Chemistry Society), July 2-4, 2014, Rouen, France.

50th International Conference on Medicinal Chemistry of the SCT (French Medicinal Chemistry Society), July 2−4, 2014, Rouen, France Janos Sapi,*,† Fred́eŕic Schmidt,‡ Luc Van Hijfte, and Pascal George †SCT Vice-President, UMR CNRS 7312, Universite ́ de Reims-Champagne-Ardenne, 51 rue Cognacq-Jay, F-51069 Reims Cedex, France ‡SCT Communication Officer, Institut Curie, Research Center, CNRS UMR3666, INSERM U1143, 26 rue d’Ulm, F-75248 Paris, France NovAliX, BioParc, 850 Blvd Seb́astien Brant, BP 30170, F-67405 Illkirch Cedex, France SCT President, Independent Scientific Expert and Adviser, F-78730 Longvilliers, France T 50th International Conference on Medicinal Chemistry, RICT (Rencontres Internationales de Chimie Theŕapeutique) 2014, focused on “Interfacing Chemical Biology and Drug Discovery” and was co-organized by the French Medicinal Chemistry Society (Societ́e ́ de Chimie Theŕapeutique, SCT) and the University of Rouen (Figure 1). Held on July 2−

[1]  Tomoyasu Ishikawa,et al.  Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.

[2]  Julia M. Schulze,et al.  The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer , 2013, ChemMedChem.

[3]  Tomoyasu Ishikawa,et al.  Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. , 2013, Cancer research.

[4]  H. Oki,et al.  Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. , 2012, Journal of medicinal chemistry.

[5]  Esther Kellenberger,et al.  Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays. , 2012, Journal of medicinal chemistry.

[6]  Camille G Wermuth,et al.  Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.

[7]  T. Katoh,et al.  Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library. , 2011, Chemistry & biology.

[8]  Elisabeth Brambilla,et al.  Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers , 2013, Science Translational Medicine.

[9]  P. Trojer,et al.  Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2. , 2014, ACS medicinal chemistry letters.

[10]  Jean Martínez,et al.  Noncationic dipeptide mimic oligomers as cell penetrating nonpeptides (CPNP). , 2010, Bioconjugate chemistry.

[11]  Richard M Walmsley,et al.  High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. , 2006, Mutation research.

[12]  A. Megens,et al.  Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia. , 2014, Journal of medicinal chemistry.

[13]  E. Carreira,et al.  Synthesis of azaspirocycles and their evaluation in drug discovery. , 2010, Angewandte Chemie.

[14]  J. Desmet,et al.  A Combinatorial Approach for the Design of Complementarity-determining Region-derived Peptidomimetics with in Vitro Anti-tumoral Activity* , 2009, The Journal of Biological Chemistry.

[15]  Zhaoming Xiong,et al.  Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[16]  Jean Martínez,et al.  Dipeptide mimic oligomer transporter mediates intracellular delivery of Cathepsin D inhibitors: a potential target for cancer therapy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[17]  K. Altmann,et al.  Total synthesis of (-)-zampanolide and structure-activity relationship studies on (-)-dactylolide derivatives. , 2012, Chemistry.

[18]  A. le Pape,et al.  The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy. , 2012, Angewandte Chemie.

[19]  H. Kimura,et al.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains , 2010, The EMBO journal.

[20]  Dirk Tomandl,et al.  Discovery of Thrombin Inhibitor Fragments from Chemical Microarray Screening , 2006 .

[21]  E. Carreira,et al.  Four-Membered Ring-Containing Spirocycles: Synthetic Strategies and Opportunities , 2014 .

[22]  U. Danielson.  Interaction Kinetic Data Generated by Surface Plasmon Resonance Biosensors and the Use of Kinetic Rate Constants in Lead Generation and Optimization , 2012 .

[23]  C. Enjalbal,et al.  A straightforward approach for cellular-uptake quantification. , 2010, Angewandte Chemie.

[24]  John A. Robinson.  Max Bergmann lecture Protein epitope mimetics in the age of structural vaccinology , 2013, Journal of peptide science : an official publication of the European Peptide Society.

[25]  Franz Schuler,et al.  Oxetanes in drug discovery: structural and synthetic insights. , 2010, Journal of medicinal chemistry.

[26]  S. Rees,et al.  The BlueScreen-384 Assay as an Indicator of Genotoxic Hazard Potential in Early-Stage Drug Discovery , 2013, Journal of biomolecular screening.

[27]  E. Chan,et al.  Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. , 2013, Chemistry & biology.

[28]  Liu Liu,et al.  A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. , 2013, Journal of medicinal chemistry.

[29]  H. Nar,et al.  A specific antidote for dabigatran: functional and structural characterization. , 2013, Blood.

[30]  J. Deschamps,et al.  Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. , 2013, Journal of the American Chemical Society.

[31]  J. Garin,et al.  Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers , 2013, EMBO molecular medicine.

[32]  Nicolas Moitessier,et al.  Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. , 2012, Journal of medicinal chemistry.

[33]  G. Winter,et al.  Phage-encoded combinatorial chemical libraries based on bicyclic peptides. , 2009, Nature chemical biology.

[34]  Stephen R. Morairty,et al.  Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics , 2012, Biological Psychiatry.

[35]  E. Carreira,et al.  Four-membered ring-containing spirocycles: synthetic strategies and opportunities. , 2014, Chemical reviews.

[36]  C. Llorens-Cortes,et al.  Structure-activity relationship studies toward the discovery of selective apelin receptor agonists. , 2014, Journal of medicinal chemistry.

[37]  M. Steinmetz,et al.  Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents , 2013, Science.

[38]  M. Hoener,et al.  Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012. , 2012, Bioorganic & medicinal chemistry letters.

[39]  F. Guilhot,et al.  Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin. , 2012, Journal of medicinal chemistry.

[40]  Yuuki Hayashi,et al.  In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors. , 2012, ACS chemical biology.

[41]  A. van Dorsselaer,et al.  Native MS: an 'ESI' way to support structure- and fragment-based drug discovery. , 2010, Future medicinal chemistry.

[42]  R. Walmsley,et al.  The involvement of WT1 in the regulation of GADD45a in response to genotoxic stress. , 2013, Mutagenesis.

[43]  L. Settimo,et al.  Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases. , 2013, Journal of medicinal chemistry.

[44]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[45]  J. Verducci,et al.  MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes , 2013, Scientific Reports.